Android app Apple app link

Catalent backs decentralised manufacture of Galapagos' CAR-T therapy

By Yahoo! Finance   |   9 hours ago
Catalent backs decentralised manufacture of Galapagos' CAR-T therapy

Catalent partners with Galapagos to enable decentralized manufacturing in the US for CAR-T therapy GLPG5101 targeting non-Hodgkin lymphoma. This collaboration aims to provide faster access to innovative treatments for patients.

Read More

Did you find this insightful?

Premium Content

This content is only available for premium members. Please become a paid member to access.

Download App

Currently, memberships can only be purchased through the app.